Quantcast
Last updated on April 18, 2014 at 15:27 EDT

Latest Natalizumab Stories

2014-03-24 12:24:47

Surveyed U.S. Payers Also Seek Improvements from New Agents in Effect on Disability, According to Findings from Decision Resources Group BURLINGTON, Mass., March 24, 2014 /PRNewswire/ -- Decision Resources Group finds that new disease-modifying therapies (DMTs) with improved efficacy in slowing disability progression present the greatest opportunity for drug developers in the treatment of relapsing-remitting multiple sclerosis (RR-MS). This finding is based on the relatively high level of...

2014-02-20 12:25:06

CHERRY HILL, N.J., Feb. 20, 2014 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publication. This vital resource provides a comprehensive overview of research findings on the ten FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions...

2013-12-12 12:26:15

Recent Changes Include Earlier and More-Aggressive Treatment, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 12, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a...

2013-11-30 23:03:24

MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Dallas, Texas (PRWEB) November 30, 2013 The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated...

2013-11-21 23:20:17

Reportbuyer.com just published a new market research report: Multiple Sclerosis: KOL Insight. London (PRWEB) November 21, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera (dimethyl fumarate) has revolutionised multiple sclerosis treatment in the US, eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of this delay with...

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...

2013-10-17 23:19:38

Reportbuyer.com just published a new market research report: Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth. London (PRWEB) October 17, 2013 Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Summary GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis...

2013-10-01 08:31:54

NEW YORK, Oct. 1, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society today announced that it has entered into a research collaboration agreement with GE Healthcare through Fast Forward, a not for profit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the United Kingdom, is aimed to aid...

2013-09-30 23:27:33

Reportbuyer.com just published a new market research report: Multiple Sclerosis: KOL Insight. London (PRWEB) September 30, 2013 An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends. The past year has seen landmark changes in multiple sclerosis, with the launch of two new novel oral products—Tecfidera (dimethyl fumarate; Biogen...

2013-09-24 08:32:16

Reformulated Copaxone and Lemtrada Are Expected to Bring High Clinical Value, According to a New Report from BioTrends Research Group EXTON, Pa., Sept. 24, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. neurologists report significantly greater overall physician satisfaction with Biogen Idec's recently-launched oral disease-modifying therapy (DMT) Tecfidera than...